Immunesensor Therapeutics Gets Australian Regulatory Nod to Begin Phase 1 Trial of IMSB301

Immunesensor Therapeutics Gets Australian Regulatory Nod to Begin Phase 1 Trial of IMSB301

By, Admin 22 August 2024

ImmuneSensor Therapeutics gets Australian regulatory nod to begin phase 1 trial of cGAS inhibitor drug candidate, IMSB301

Overview

ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting the cGAS-STING pathway to address diverse peripheral and CNS indications in inflammation, autoimmunity and oncology, announced that it has received Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to initiate a phase 1 randomized placebo-controlled, double-blinded clinical trial of its lead anti-inflammatory and autoimmunity drug candidate, IMSB301, in healthy volunteers. IMSB301 is a novel, orally available small molecule cGAS inhibitor that is being developed for the treatment of inflammatory and autoimmune diseases.

Words from the CEO: ImmuneSensor

  • Receiving HREC approval and CTN clearance for the first clinical trial of our novel cGAS inhibitor is a significant milestone for ImmuneSensor as we pursue our goal to bring innovative therapeutic interventions to those battling autoimmune and other inflammatory diseases,” said Tom Dubensky, Ph.D., ImmuneSensor’s president and chief executive officer.
  • The initial dose finding portion of our phase 1 trial of IMSB301 in healthy volunteers will provide important early safety and target engagement data that will inform rapid advancement to phase 1b/2 clinical studies in patients with severe inflammatory diseases, including Aicardi Goutières syndrome (AGS), a rare inflammatory disease that is specifically driven by chronic activation of the cGAS pathway in these patients, and in defined patient populations with systemic lupus erythematosus (SLE).

About The Trial

  • The phase 1 randomized, placebo-controlled, double-blind clinical trial is designed to evaluate the safety and tolerability, and pharmacokinetics (PK) of single and multiple escalating doses of IMSB301 and to demonstrate target engagement. 
  • The study will enroll healthy volunteers in cohorts of eight subjects (two will be given placebo and six dosed with IMSB301) given up to five single ascending dose (SAD) levels over two days, and subsequently up to three multiple ascending dose (MAD) levels. 
  • The primary endpoint is safety and tolerability, PK will be assessed in both SAD and MAD arms and target engagement will be evaluated using an ex vivo whole blood DNA stimulation assay in the MAD arm.

IMSB301: Targeting the cGAS-STING Pathway

  • The cGAS-STING pathway works to detect both host-derived and foreign cytoplasmic DNA produced as a result of infection or cell damage due to inflammation or malignancy. 
  • In autoimmune diseases, the innate immune response is chronically activated, directly promoting inflammation and the development of autoimmunity, both in the periphery and the central nervous system (CNS).
  • IMSB301 is a novel, orally available small molecule designed to specifically inhibit the cGAS enzyme and stop pathologic inflammation. 
  • In preclinical studies, IMSB301 has been demonstrated to be a potent and specific inhibitor of cGAS enzymatic activity that results in a profound suppression of cytokine production and rescue of the disease phenotype and premature death in a model of AGS. 
  • ImmuneSensor is developing IMSB301 initially in cGAS-driven Type I interferonopathies including AGS and SLE. 
  • IMSB301 has the potential to address other diverse therapeutic areas that are characterized by cGAS-driven inflammation including diabetic kidney diseases, age-related macular degeneration, and other autoimmune disorders.

About AGS

  • AGS is a rare genetic severe inflammatory disease of immune cells affecting the brain (demyelination) and peripheral tissues (lungs, liver, heart, skin) caused by mutations in upstream cytosolic nuclease genes, including TREX-1, that triggers chronic production of type I interferon (IFN-I) and additional pro-inflammatory cytokines resulting from chronic activation of cGAS and the production of downstream signalling molecules. 
  • The disease has no cure and is currently treated with drugs designed to manage symptoms.

About SLE

  • SLE is a complex autoimmune disorder that can be associated with the dysregulated production of IFN-I and other pro-inflammatory cytokines, which is thought to play a pivotal role in the pathogenesis of the disease. 
  • The disease characterized by heterogeneous clinical manifestations, involving the skin, blood vessels, kidneys and central nervous system that can result in serious organ damage and appears to develop when individuals with a genetic predisposition for the disease come into contact with an environmental “trigger.” 
  • The CDC estimates that approximately 204,000 people in the United States have SLE, the most common type of lupus, with nine times as many women as men likely to develop the disease. 
  • Current standard of care involves treatment with anti-inflammatory drugs and immunosuppressants.

About ImmuneSensor

ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating immunity, by Dr. Zhijian Chen’s laboratory at the University of Texas Southwestern Medical Center, a breakthrough that has profoundly impacted both the scientific and pharmaceutical fields.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!